Trial Outcomes & Findings for Abemaciclib With or Without Atezolizumab for mCRPC (NCT NCT04751929)

NCT ID: NCT04751929

Last Updated: 2025-10-02

Results Overview

The percentage of participants alive and progression-free at 6 months, as assessed by RECIST 1.1 and PCWG3.

• Recruitment status: ACTIVE_NOT_RECRUITING
• Study phase: PHASE2
• Target enrollment: 19 participants
• Primary outcome timeframe: 6 months
• Results posted on: 2025-10-02

Participant Flow

Participant milestones

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
Overall Study STARTED	7	8	4	0
Overall Study COMPLETED	0	0	0	0
Overall Study NOT COMPLETED	7	8	4	0

Reasons for withdrawal

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
Overall Study Withdrawal by Subject	2	0	0	0
Overall Study Rising PSA	0	1	0	0
Overall Study Adverse Event	1	2	0	0
Overall Study Progressive Disease	3	4	4	0
Overall Study Death	1	1	0	0

Baseline Characteristics

Abemaciclib With or Without Atezolizumab for mCRPC

Baseline characteristics by cohort

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) n=7 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) n=8 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) n=4 Participants Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	Total n=19 Participants Total of all reporting groups
Age, Continuous	71 years n=5 Participants	70 years n=7 Participants	69 years n=5 Participants	—	70 years n=21 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	—	0 Participants n=21 Participants
Sex: Female, Male Male	7 Participants n=5 Participants	8 Participants n=7 Participants	4 Participants n=5 Participants	—	19 Participants n=21 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	—	0 Participants n=21 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	—	1 Participants n=21 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	—	0 Participants n=21 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	—	2 Participants n=21 Participants
Race (NIH/OMB) White	6 Participants n=5 Participants	7 Participants n=7 Participants	3 Participants n=5 Participants	—	16 Participants n=21 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	—	0 Participants n=21 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	—	0 Participants n=21 Participants
ECOG performance status 0; Fully active, able to carry on all pre-disease activities without restriction (best outcome)	3 Participants n=5 Participants	6 Participants n=7 Participants	3 Participants n=5 Participants	—	12 Participants n=21 Participants
ECOG performance status 1; Restricted in physically strenuous activity but ambulatory and able to carry out light work	4 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	—	7 Participants n=21 Participants

PRIMARY outcome

Timeframe: 6 months

Population: No patients were enrolled in the Monotherapy (Non-Randomized) or the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arms. One patient in each of the following arms, Biomarker-Unselected Abemaciclib Monotherapy (Randomized) and CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized), did not initiate study treatment and was therefore excluded from the analysis.

The percentage of participants alive and progression-free at 6 months, as assessed by RECIST 1.1 and PCWG3.

Outcome measures

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) n=7 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) n=8 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) n=4 Participants Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
6-month Progression Free Survival (PFS) Rate	100 percentage of participants Interval 100.0 to 100.0	NA percentage of participants The median and its 95% CI have not been reached, as the KM curve has not crossed the 50% point.	50 percentage of participants Interval 10.0 to 81.0	—

PRIMARY outcome

Timeframe: 6 months

Population: No patients were enrolled in the Monotherapy (Non-Randomized) or the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arms. One patient in each of the following arms, Biomarker-Unselected Abemaciclib Monotherapy (Randomized) and CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized), did not initiate study treatment and was therefore excluded from the analysis.

The percentage of evaluable patients who had radiographic response (complete response or partial response) by RECIST 1.1 criteria OR 50% decline in PSA from pretreatment baseline per PCWG3 criteria.

Outcome measures

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) n=7 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) n=8 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) n=4 Participants Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
Objective Response Rate (ORR)	0 percentage of participants Interval 0.0 to 0.0	12.5 percentage of participants Interval 0.6 to 47.0	0 percentage of participants Interval 0.0 to 0.0	—

PRIMARY outcome

Timeframe: DLTs were collected while participants on treatment. Treatment duration up to 18 months.

Population: Only for Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) and CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arms

DLT was assessed by Bayesian Continuous Toxicity Monitoring in Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) and CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arms.

Outcome measures

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) n=8 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
Number of Participants Experiencing Dose Limiting Toxicity (DLT) in Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) and CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Arms	0 Participants	4 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: From treatment initiation to end of treatment, with follow-up for up to 2 years after treatment discontinuation

Proportion of evaluable patients who had complete response (CR), partial response (PR) or stable disease (SD) as their best response to treatment in arms biomarker-unselected abemaciclib monotherapy (randomized), biomarker-unselected abemaciclib + atezolizumab (randomized), and CDK12 mutation abemaciclib + atezolizumab (non-randomized)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From the date of first documented CR or PR until disease progression or death, or up to 2 years

The time from the first documented complete response (CR) or partial response (PR) to the earliest date of disease progression or death, whichever occurs first, as determined by PCWG3 criteria.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From treatment initiation until treatment discontinuation for any reason

The length of time from the first administration of study treatment to the date of treatment discontinuation for any reason

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From treatment initiation until documented disease progression, or assessed up to 2 years

The duration of time from the first administration of study treatment to the date of first documented disease progression, as determined by Prostate Cancer Working Group 3 (PCWG3) criteria. Patients without documented progression are censored at the last tumor assessment date.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 months

Population: No patients were enrolled in the Monotherapy (Non-Randomized) or the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arms. One patient in each of the following arms, Biomarker-Unselected Abemaciclib Monotherapy (Randomized) and CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized), did not initiate study treatment and was therefore excluded from the analysis.

The percentage of participants who are alive 12 months after the start of treatment

Outcome measures

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) n=7 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) n=8 Participants Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) n=4 Participants Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
12-month Overall Survival (OS)	83 percentage of patients Interval 39.0 to 97.0	50 percentage of patients Interval 20.0 to 74.0	75 percentage of patients Interval 22.0 to 95.0	—

SECONDARY outcome

Timeframe: From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose

Number of participants experiencing adverse events, categorized by the maximum grade according to CTCAE v5.0.

Outcome measures

Outcome data not reported

Adverse Events

Biomarker-Unselected Abemaciclib Monotherapy (Randomized)

Serious events: 3 serious events

Other events: 6 other events

Deaths: 5 deaths

Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)

Serious events: 4 serious events

Other events: 8 other events

Deaths: 7 deaths

CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)

Serious events: 0 serious events

Other events: 4 other events

Deaths: 4 deaths

CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) n=7 participants at risk Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) n=8 participants at risk Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) n=4 participants at risk Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
Blood and lymphatic system disorders Anemia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Cardiac disorders Atrial fibrillation	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Abdominal pain	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Hepatobiliary disorders Hepatic failure	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Infections and infestations Joint infection	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Infections and infestations Sepsis	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Infections and infestations Skin infection	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Infections and infestations Urinary tract infection	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Alkaline phosphatase increased	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Blood bilirubin increased	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Creatinine increased	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Platelet count decreased	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Stroke	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.

Other adverse events

Measure	Biomarker-Unselected Abemaciclib Monotherapy (Randomized) n=7 participants at risk Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily Abemaciclib: Taken orally 2x daily	Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) n=8 participants at risk Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized) n=4 participants at risk Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle Atezolizumab: Intravenously Day 1 of 21 day cycle	CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle Abemaciclib: Taken orally 2x daily Atezolizumab: Intravenously Day 1 of 21 day cycle
Blood and lymphatic system disorders Anemia	71.4% 5/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	87.5% 7/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	100.0% 4/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Cardiac disorders Atrial fibrillation	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Cardiac disorders Cardiac disorders - Other, specify	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Cardiac disorders Palpitations	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Cardiac disorders Sinus tachycardia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Ear and labyrinth disorders Vertigo	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Endocrine disorders Hyperthyroidism	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Endocrine disorders Hypothyroidism	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Abdominal pain	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Constipation	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Diarrhea	71.4% 5/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	62.5% 5/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Dry mouth	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Dysphagia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Gastroesophageal reflux disease	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	50.0% 2/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Nausea	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	37.5% 3/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	50.0% 2/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Stomach pain	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Gastrointestinal disorders Vomiting	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
General disorders Edema limbs	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	50.0% 2/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
General disorders Fatigue	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	62.5% 5/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	50.0% 2/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
General disorders Fever	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	37.5% 3/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
General disorders Flu like symptoms	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
General disorders General disorders and administration site conditions - Other, specify	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
General disorders Pain	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Hepatobiliary disorders Hepatobiliary disorders - Other, specify	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Immune system disorders Allergic reaction	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Infections and infestations Infections and infestations - Other, specify	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Infections and infestations Tooth infection	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Infections and infestations Upper respiratory infection	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Alanine aminotransferase increased	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Alkaline phosphatase increased	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	37.5% 3/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	75.0% 3/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Aspartate aminotransferase increased	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	37.5% 3/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Blood bilirubin increased	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Cardiac troponin T increased	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Creatinine increased	57.1% 4/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	62.5% 5/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Investigations - Other, specify	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Neutrophil count decreased	57.1% 4/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	50.0% 4/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Platelet count decreased	57.1% 4/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	37.5% 3/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations Weight loss	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Investigations White blood cell decreased	42.9% 3/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	37.5% 3/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Anorexia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Dehydration	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Hyperglycemia	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Hyperlipidemia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Hypoalbuminemia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Hypocalcemia	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Hypokalemia	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Hyponatremia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Metabolism and nutrition disorders Obesity	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Arthritis	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Back pain	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	75.0% 3/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Bone pain	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Flank pain	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Generalized muscle weakness	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Joint range of motion decreased	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Musculoskeletal and connective tissue disorder - Other, specify	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Musculoskeletal and connective tissue disorders Pain in extremity	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumor pain	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Dizziness	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Dysgeusia	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Headache	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Nervous system disorders - Other, specify	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Peripheral sensory neuropathy	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Presyncope	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Nervous system disorders Syncope	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Psychiatric disorders Anxiety	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Psychiatric disorders Depression	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Psychiatric disorders Insomnia	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Renal and urinary disorders Acute kidney injury	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Renal and urinary disorders Dysuria	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Renal and urinary disorders Hematuria	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Renal and urinary disorders Urinary frequency	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Renal and urinary disorders Urinary tract pain	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Renal and urinary disorders Urinary urgency	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Reproductive system and breast disorders Testicular pain	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Allergic rhinitis	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Cough	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Dyspnea	57.1% 4/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Epistaxis	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Respiratory, thoracic and mediastinal disorders - Other, specify	28.6% 2/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Respiratory, thoracic and mediastinal disorders Sleep apnea	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Skin and subcutaneous tissue disorders Alopecia	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Skin and subcutaneous tissue disorders Nail changes	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Skin and subcutaneous tissue disorders Rash maculo-papular	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders - Other, specify	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Skin and subcutaneous tissue disorders Skin ulceration	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Vascular disorders Hot flashes	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Vascular disorders Hypertension	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 2/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Vascular disorders Hypotension	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	12.5% 1/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Vascular disorders Thromboembolic event	14.3% 1/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.
Vascular disorders Vascular disorders - Other, specify	0.00% 0/7 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	0.00% 0/8 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	25.0% 1/4 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.	— 0/0 • From treatment initiation through 100 days after last dose for treatment-emergent adverse events, and up to 2 years after last dose. Maximum treatment duration was 18 months. A serious adverse event is classified using physician's discretion. All adverse events resulting in death, life threatening events, significant disability, prolonged hospitalization, congenital abnormality/birth defect, or new cancer will be considered a serious adverse event. No patients were accrued in the CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arm.

Additional Information

Atish Choudhury, MD PhD

Dana-Farber Cancer Institute

Phone: 6176326328

Email: atish_choudhury@dfci.harvard.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place